Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  PPD, Inc.    PPD


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

PPD : Accelerated Enrollment Solutions Wins SCRS Site Tank Award

10/26/2020 | 07:11am EST

Virtual screening team honored for deploying innovative technology during pandemic

Accelerated Enrollment Solutions (AES), a business of PPD, Inc. (Nasdaq:PPD), has been named the winner of the 2020 Site Tank Award by the Society for Clinical Research Sites (SCRS). AES received the award for developing and deploying an innovative technology platform to prescreen clinical trial patients online, in real time and worldwide, without having to visit a clinical research site in person.

Nearly 95 percent of all AES prescreening visits are now virtual, allowing the clinical trials that AES supports to continue uninterrupted during the coronavirus pandemic.

The prescreening technology is utilized throughout the AES global network of more than 180 sites by the AES virtual screening team, a dedicated group that supports an entire country’s site model. The team approach allows AES to align consent and compliance procedures among all sites and consistently train all clinical employees on best practices using a first office visit checklist and performance management dashboard.

“Our team rolled out the prescreening platform in less than two weeks in response to the pandemic, achieving remarkable speed of implementation at scale,” said Jill Pellegrino, general manager of AES. “We are grateful to SCRS for recognizing our commitment to patient and staff safety during this unprecedented time. Patient feedback on the technology has been phenomenal, with high satisfaction ratings and near-global adoption by prospective trial participants across the regions in which we operate.”

The SCRS Site Tank award recognizes research sites that have developed innovative technology solutions that enhance and improve clinical research operations and transform business models. The top three finalists, selected by an independent judging panel, were invited to virtually present their Site Tank ideas to an audience of sites, sponsors and contract research organizations (CROs) attending the 15th annual Global Site Solutions Summit, where the winner was announced.

About AES

Accelerated Enrollment Solutions is a business of PPD that offers sponsors and CROs distinctive site conduct and patient access solutions. These solutions are available as discrete services or integrated to provide a cohesive and highly differentiated trial acceleration strategy for insourced or outsourced clinical studies, all under results-based commercial terms. For more information, visit www.globalaes.com.

About PPD

PPD is a leading global CRO providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 25,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.

This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K, which is available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

© Business Wire 2020
All news about PPD, INC.
01/14PPD, INC. : Entry into a Material Definitive Agreement, Termination of a Materia..
01/11PPD, INC. : Regulation FD Disclosure (form 8-K)
01/11EQS-NEWS : Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM..
01/06DAI ICHI KARKARIA : Gets Closure Order for Unit from Gujarat Pollution Control B..
01/04PPD : to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020MODERNA : Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.
2020PPD, INC. : Change in Directors or Principal Officers (form 8-K)
2020PPD : Recognized as a Best Place to Work in Greater China
2020EQS-NEWS : Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in..
2020MARKET CHATTER : US Clears New Drug Application for LG Chem’s Liver Diseas..
More news
Financials (USD)
Sales 2020 4 586 M - -
Net income 2020 140 M - -
Net Debt 2020 3 428 M - -
P/E ratio 2020 89,3x
Yield 2020 -
Capitalization 12 539 M 12 539 M -
EV / Sales 2020 3,48x
EV / Sales 2021 3,06x
Nbr of Employees 23 000
Free-Float 61,2%
Chart PPD, INC.
Duration : Period :
PPD, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PPD, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 16
Average target price 39,50 $
Last Close Price 35,86 $
Spread / Highest target 19,9%
Spread / Average Target 10,2%
Spread / Lowest Target -12,2%
EPS Revisions
Managers and Directors
David S. Simmons Chairman & Chief Executive Officer
William Jacob Sharbaugh Chief Operating Officer
Christopher G. Scully CFO, Treasurer, Executive VP & Assistant Secretary
David Johnston Executive VP-Global Clinical Development
Karen Kaucic Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PPD, INC.4.79%12 539
MODERNA, INC.19.79%49 519
LONZA GROUP AG4.32%49 499
CELLTRION, INC.-13.09%38 562
SEAGEN INC.8.94%34 515